Y-mabs Therapeutics Inc. (YMAB)

$11.59

-0.11

(-0.94%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $11.45
    $11.76
    $11.59
    downward going graph

    1.21%

    Downside

    Day's Volatility :2.64%

    Upside

    1.45%

    downward going graph
  • $4.60
    $20.90
    $11.59
    downward going graph

    60.31%

    Downside

    52 Weeks Volatility :77.99%

    Upside

    44.55%

    downward going graph

Returns

PeriodY-mabs Therapeutics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-23.55%
6.4%
0.0%
6 Months
18.63%
6.0%
0.0%
1 Year
76.14%
8.5%
0.0%
3 Years
-66.93%
14.6%
-20.8%

Highlights

Market Capitalization
513.4M
Book Value
$2.26
Earnings Per Share (EPS)
-0.49
Wall Street Target Price
21.33
Profit Margin
-25.64%
Operating Margin TTM
-34.66%
Return On Assets TTM
-12.02%
Return On Equity TTM
-20.93%
Revenue TTM
84.5M
Revenue Per Share TTM
1.94
Quarterly Revenue Growth YOY
-1.6%
Gross Profit TTM
57.7M
EBITDA
-24.4M
Diluted Eps TTM
-0.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.53
EPS Estimate Next Year
-0.58
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    76%Buy
    15%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Y-mabs Therapeutics Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 84.04%

Current $11.59
Target $21.33

Technicals Summary

Sell

Neutral

Buy

Y-mabs Therapeutics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Y-mabs Therapeutics Inc.
Y-mabs Therapeutics Inc.
-3.42%
18.63%
76.14%
-66.93%
-48.6%
Moderna, Inc.
Moderna, Inc.
-9.19%
21.5%
-4.18%
-62.27%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.99%
12.81%
44.78%
82.21%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.34%
24.69%
58.81%
196.23%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.88%
11.69%
35.62%
150.46%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Y-mabs Therapeutics Inc.
Y-mabs Therapeutics Inc.
NA
NA
NA
-0.53
-0.21
-0.12
NA
2.26
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Y-mabs Therapeutics Inc.
Y-mabs Therapeutics Inc.
Buy
$513.4M
-48.6%
NA
-25.64%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Y-mabs Therapeutics Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 23.36M → 19.93M (in $), with an average decrease of 14.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -988.0K → -6.62M (in $), with an average decrease of 571.0% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 196.2% return, outperforming this stock by 263.1%

Institutional Holdings

  • BlackRock Inc

    6.51%
  • Paradigm Biocapital Advisors LP

    5.09%
  • Sofinnova Ventures

    5.00%
  • Vanguard Group Inc

    4.72%
  • Polar Capital Holdings PLC

    4.17%
  • Point72 Asset Management, L.P.

    3.48%

Company Information

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Organization
Y-mabs Therapeutics Inc.
Employees
100
CEO
Mr. Thomas Gad
Industry
Health Technology

FAQs